Next Article in Journal
Biomarkers of Immune Checkpoint Inhibitor Efficacy in Cancer
Previous Article in Journal
A Fresh Look at Therapeutic Advances in Soft-Tissue Sarcoma
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Review

Systemic Therapy in Pediatric-Type Soft-Tissue Sarcoma

by 1,2, 3 and 3,4,5,*
1
Department of Pediatric Oncology, Royal Children’s Hospital, Melbourne, Australia
2
Adolescent and Young Adult Cancer Service, Peter MacCallum Cancer Centre, Melbourne, Australia
3
Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada
4
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
5
Division of Medical Oncology and Hematology, Sinai Health System, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2020, 27(s1), 6-16; https://doi.org/10.3747/co.27.5481
Received: 11 November 2019 / Revised: 7 December 2019 / Accepted: 2 January 2020 / Published: 1 February 2020
Soft-tissue sarcoma (sts) is rare and represents approximately 7% of cancers in children and in adolescents less than 20 years of age. Rhabdomyosarcoma (rms) is most prevalent in children less than 10 years of age and peaks again during adolescence (16–19 years of age). Multi-agent chemotherapy constitutes the mainstay of treatment for rms. In other non-rhabdomyosarcoma soft-tissue tumours, such as synovial sarcoma, evidence for routine use of chemotherapy is less robust, and alternative treatment options, including targeted agents and immunotherapy, are being explored. In this review, we focus on chemotherapy for pediatric-type rms and discuss the advances and challenges in systemic treatment for select non-rhabdomyosarcoma soft-tissue tumours in children and adolescents. We support an increasingly cooperative approach for treating pediatric and adult sts.
Keywords: chemotherapy; pediatrics; adolescents and young adults; ayas; rhabdomyosarcoma; nonrhabdomyosarcoma; soft-tissue sarcoma chemotherapy; pediatrics; adolescents and young adults; ayas; rhabdomyosarcoma; nonrhabdomyosarcoma; soft-tissue sarcoma
MDPI and ACS Style

Ingley, K.M.; Cohen-Gogo, S.; Gupta, A.A. Systemic Therapy in Pediatric-Type Soft-Tissue Sarcoma. Curr. Oncol. 2020, 27, 6-16. https://doi.org/10.3747/co.27.5481

AMA Style

Ingley KM, Cohen-Gogo S, Gupta AA. Systemic Therapy in Pediatric-Type Soft-Tissue Sarcoma. Current Oncology. 2020; 27(s1):6-16. https://doi.org/10.3747/co.27.5481

Chicago/Turabian Style

Ingley, K.M., S. Cohen-Gogo, and A.A. Gupta. 2020. "Systemic Therapy in Pediatric-Type Soft-Tissue Sarcoma" Current Oncology 27, no. s1: 6-16. https://doi.org/10.3747/co.27.5481

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop